I think the first one gives them sufficient coverage because it covers the formulation. There is very little difference between the two patents. I would have to find my IHUB post where I explained the differences but off the top of my head , this one is for methods of making a drug abuse resistant and the other patent if more about the formulation of an abuse resistant drug. Its legal semantics and why the double patenting charge but I think ultimately Elite wants it for licensing and additional IP coverage.